CRBU Caribou Biosciences (CRBU) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001619856
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
71
13F, latest reported quarter
Caribou Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Caribou Biosciences, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 24, 2026.
- The trade is 8.5% of the 73,125 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Kelly Timothy P sold about $12.0K of CRBU on Feb 25, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.0% of the 79,353 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Kelly Timothy P sold about $6.2K of CRBU on Feb 24, 2026, the largest insider sale at the company since 2023; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (4 buys, 1 sale), the last on Feb 21, 2025.
- -48.4% median (-48.4% mean) 90-day return after 2 previous buys.
- The trade is 1.4% of the 481,564 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer MCCLUNG BARBARA G sold about $13.6K of CRBU on Feb 24, 2026, the largest insider sale at the company since 2023; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 21, 2025.
- The trade is 6.6% of the 104,998 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Khan Ruhi Ahmad sold about $13.6K of CRBU on Feb 24, 2026, the largest insider sale at the company since 2023; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.6% of the 68,523 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Albertson Tina M. sold about $2.1K of CRBU on Feb 24, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
71 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
+11.7% year over year
more than 61% of Pharma & Biotech
Margin
-1327.4% net margin
below 89% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-26) · 13.1 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CRBU
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-80.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CRBU: institutional holders (13F)
13F holdings, latest reported quarter
7,815,843 sh
$13.8M
4,690,431 sh
$7.9M
4,208,568 sh
$7.4M
3,650,796 sh
$6.4M
2,773,545 sh
$4.9M
Congress trades in CRBU
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CRBU planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CRBU mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AXS Green Alpha ETF
$355.3K position · as of 2026-06-30
0.6%
Invesco NASDAQ Future Gen 200 ETF
$95.4K position · as of 2026-05-31
0.5%
Global X Genomics & Biotechnology ETF
$160.9K position · as of 2026-05-31
0.3%
Ultra-Small Company Market Fund
$199.8K position · as of 2026-06-30
0.1%
BRUCE FUND
$440.0K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$542.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
2 active
1
Not applicable
1 active
What changed recently
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non
2026-10-20 · Completion moved 2025-08 → 2025-09-11
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non
2026-10-20 · Unknown → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 71 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CRBU financials
Revenue growth
+11.7%
XBRL, annual
Net margin
-1327.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRBU
| FY Dec 2025 | $11.2M |
| FY Dec 2024 | $10.0M |
| FY Dec 2023 | $34.5M |
| FY Dec 2022 | $13.9M |
| FY Dec 2021 | $9.6M |
| Jun 2026 | $1.5M |
| Mar 2026 | $2.4M |
| Dec 2025 | $3.9M |
| Sep 2025 | $2.2M |
| Jun 2025 | $2.7M |
| Mar 2025 | $2.4M |
| Dec 2024 | $2.1M |
| Sep 2024 | $2.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-1,030%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CRBU
| FY Dec 2025 | -1,327% |
| FY Dec 2024 | -1,492% |
| FY Dec 2023 | -296.1% |
| FY Dec 2022 | -717.8% |
| FY Dec 2021 | -697.3% |
| Jun 2026 | -1,620% |
| Mar 2026 | -1,047% |
| Dec 2025 | -672.1% |
| Sep 2025 | -1,253% |
| Jun 2025 | -2,028% |
| Mar 2025 | -1,700% |
| Dec 2024 | -1,709% |
| Sep 2024 | -1,714% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$95.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CRBU
| FY Dec 2025 | -$112.4M |
| FY Dec 2024 | -$143.1M |
| FY Dec 2023 | -$104.9M |
| FY Dec 2022 | -$97.4M |
| FY Dec 2021 | -$34.6M |
| Jun 2026 | -$22.8M |
| Mar 2026 | -$27.1M |
| Dec 2025 | -$20.6M |
| Sep 2025 | -$25.3M |
| Jun 2025 | -$28.7M |
| Mar 2025 | -$37.8M |
| Dec 2024 | -$36.0M |
| Sep 2024 | -$33.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-78.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CRBU
| FY Dec 2025 | -79.0% |
| FY Dec 2024 | -48.0% |
| FY Dec 2023 | -30.5% |
| FY Dec 2022 | -28.9% |
| FY Dec 2021 | -36.7% |
| Jun 2026 | -78.3% |
| Mar 2026 | -83.5% |
| Dec 2025 | -79.0% |
| Sep 2025 | -74.3% |
| Jun 2025 | -68.9% |
| Mar 2025 | -52.8% |
| Dec 2024 | -48.0% |
| Sep 2024 | -43.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-56.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRBU
| FY Dec 2025 | -60.6% |
| FY Dec 2024 | -40.0% |
| FY Dec 2023 | -25.3% |
| FY Dec 2022 | -24.4% |
| FY Dec 2021 | -28.0% |
| Jun 2026 | -56.9% |
| Mar 2026 | -63.0% |
| Dec 2025 | -60.6% |
| Sep 2025 | -58.3% |
| Jun 2025 | -55.3% |
| Mar 2025 | -43.5% |
| Dec 2024 | -40.0% |
| Sep 2024 | -36.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-69.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CRBU
| FY Dec 2025 | -68.6% |
| FY Dec 2024 | -48.5% |
| FY Dec 2023 | -31.0% |
| FY Dec 2022 | -27.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -69.1% |
| Mar 2026 | -70.3% |
| Dec 2025 | -68.6% |
| Sep 2025 | -66.3% |
| Jun 2025 | -62.8% |
| Mar 2025 | -52.5% |
| Dec 2024 | -48.5% |
| Sep 2024 | -44.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-181.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield CRBU
| FY Dec 2025 | -75.6% |
| FY Dec 2024 | -99.4% |
| FY Dec 2023 | -20.7% |
| FY Dec 2022 | -25.4% |
| FY Dec 2021 | -3.8% |
| Jun 2026 | -54.9% |
| Mar 2026 | -55.4% |
| Dec 2025 | -75.6% |
| Sep 2025 | -58.9% |
| Jun 2025 | -115.9% |
| Mar 2025 | -167.5% |
| Dec 2024 | -99.4% |
| Sep 2024 | -73.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CRBU
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M |
| EPS (diluted) | -1.59 | -1.65 | -1.38 | -1.64 |
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M |
| Cash | $12.4M | $16.3M | $51.2M | $58.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
CRBU Stock Sonar score 4/7 axes
Find similar shapesCompareCRBU ranks highest on institutional and government (56th percentile) and profitability (39th), and lowest on risk and compliance (28th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
